Can Losartan Cause Pancreatitis?
Yes, losartan can cause acute pancreatitis, but this is an extremely rare adverse effect, and the overall evidence suggests that angiotensin II receptor blockers (ARBs) like losartan may actually be protective against pancreatitis compared to other antihypertensive medications.
Evidence Assessment
The FDA drug label for losartan does not list pancreatitis as a recognized adverse effect 1. However, isolated case reports document losartan-induced pancreatitis 2, 3, 4, establishing biological plausibility through case reports with positive rechallenge in some instances.
The most important and recent population-based evidence contradicts the case reports:
Large-Scale Population Studies Show Protective Effect
A 2017 Swedish nationwide case-control study of 6,161 acute pancreatitis cases found that ARB use was associated with a 23% decreased risk of acute pancreatitis (adjusted OR 0.77,95% CI 0.69-0.86) compared to non-users 5. This protective effect was significant for both severe (OR 0.71) and mild pancreatitis (OR 0.81).
A 2017 Taiwanese population-based case-control study of 1,449 hypertensive patients with acute pancreatitis found no significant association between losartan use and acute pancreatitis (adjusted OR 0.96,95% CI 0.68-1.37 for current use) 6.
Contrasting Evidence for ACE Inhibitors
Importantly, a 2022 UK population-based cohort study found that ACE inhibitors (not ARBs) were associated with increased pancreatitis risk (HR 1.45,95% CI 1.15-1.83), while ARBs showed no increased risk (HR 0.88,95% CI 0.60-1.31) 7. This distinction is critical—the pancreatitis risk appears specific to ACE inhibitors, not the ARB class that includes losartan.
Clinical Implications
When to Suspect Drug-Induced Pancreatitis
- Abdominal pain developing after losartan initiation (typically within days to weeks, though delayed onset has been reported 3)
- Elevated lipase/amylase with imaging confirmation
- Exclusion of common causes: gallstones, alcohol, hypertriglyceridemia (>500 mg/dL), hypercalcemia, other medications 8
Management Algorithm
If pancreatitis develops on losartan:
Alternative antihypertensive selection:
For patients with prior pancreatitis:
- ARBs (including losartan) are not contraindicated based on population data showing protective effects 5
- Exercise clinical judgment for individual risk-benefit assessment
Important Caveats
The case reports represent idiosyncratic reactions occurring in isolated patients, while the population-level data from thousands of patients shows either no association or a protective effect. The number needed to harm, even if a causal relationship existed, would be extraordinarily high.
Do not withhold losartan solely due to pancreatitis concerns in patients who would otherwise benefit from ARB therapy for hypertension, heart failure, or diabetic nephropathy 9, 10. The cardiovascular and renal benefits far outweigh the theoretical pancreatitis risk.
The mechanism by which ARBs might protect against pancreatitis involves angiotensin II receptors' role in regulating pancreatic microcirculation and secretion 2, though the exact pathophysiology remains incompletely understood.